Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Apr
16
Today In Oncology
Is Standard of Care Optimal for the Individual Patient?
LuPSMA-617 and Pembrolizumab in mCRPC
ASH-ISTH Create Guidelines for Pediatric VTE Prophylaxis
Asbestos-Free Talc Not Associated With Increased Risk for Respiratory Cancers
New Molecular-Based Model for Classification and Risk in Chronic Myelomonocytic Leukemia
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo